Prima gets go ahead for ovarian cancer vaccine trial in US
Wednesday, 02 September, 2009
Prima BioMed is a step closer to commercialisation of its ovarian cancer vaccine, CVac, with the US Food and Drug Administration giving the go ahead on a Phase IIb trial.
This follows positive results from a Phase IIa trial conducted in Australia in 2006, with the final results announced in March 2007.
The new trial will be conducted at the Fred Hutchinson Cancer Centre in Seattle in the US and will involve 60 patients. It will seek to assess the efficacy of CVac to stimulate the patient's own immune system to target and destroy tumours.
CVac is administered post-surgery and post-chemotherapy to delay the relapse and control the metastases of the cancer.
Prima BioMed's (ASX:PRR) share price lifted 10% to $0.11 following the announcement.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
